Normix (Rifaximin)

Rifaximin is an antibacterial agent used to manage gastrointestinal infections and related disorders.

• Traveler’s diarrhea: reduces the duration and severity of acute bacterial diarrhea acquired during travel.
• Irritable bowel syndrome with diarrhea (IBS‑D): improves stool consistency and abdominal discomfort in IBS‑D patients.
• Hepatic encephalopathy: lowers blood ammonia levels to help prevent recurrence of encephalopathic episodes.
• Small intestinal bacterial overgrowth (SIBO): eradicates excess bacterial growth to alleviate bloating, gas and diarrhea.

• Rifaximin exerts its antibacterial effect by binding to the β‑subunit of bacterial DNA‑dependent RNA polymerase, thereby inhibiting the initiation of RNA synthesis. This action blocks transcription of essential genes, leading to bacteriostatic activity against a broad range of Gram‑positive and Gram‑negative organisms in the intestinal lumen, with minimal systemic absorption. Consequently, therapeutic concentrations remain confined to the gut, reducing the risk of systemic side effects while providing targeted antimicrobial activity.

Rifaximin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Nausea: mild to moderate feeling of queasiness.
• Headache: transient cranial pain.
• Flatulence: increased intestinal gas.
• Abdominal discomfort: mild cramps or pain.
• Diarrhea: paradoxical increase in stool frequency.
• Vomiting: occasional emesis.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis requiring medical attention.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevation: abnormal hepatic function tests.
• Severe hypersensitivity: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing rifaximin, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: assess kidney function before initiating therapy.
• Hepatic dysfunction: monitor liver enzymes during treatment.
• Concomitant antibiotics: avoid use with broad‑spectrum agents that may alter gut flora.
• Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited.
• Drug resistance: limit duration to recommended course to reduce selection of resistant organisms.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Rifaximin may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased risk of bleeding; monitor INR closely.
• Macrolide antibiotics (e.g., erythromycin): may increase rifaximin concentrations; avoid co‑administration.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: possible reduction in effectiveness; advise backup contraception.
• Cyclosporine: may increase cyclosporine levels; monitor renal function.
• Bile acid sequestrants: may reduce rifaximin absorption; separate dosing by at least 2 hours.